DOCSLIB.ORG

Supplementary Table II

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Table II Supplementary Table II. List of the active principles divided according to the target apparatus and pharmacological mechanisms of action, with indication of the type of side effect using a number from 1 to 4 (1: ototoxic drugs; 2: drugs inducing tinnitus; 3: drugs inducing vertigo or dizziness; 4: drugs inducing generic hearing disorders) and the scale of severity according to Adverse Drug Reactions (ADR) - a: very common (≥ 10%); b: common (≥ 1% e < 10%); c: uncommon (≥ 0.1% e <1%); d: rare ( ≥ 0.01% e < 0.1%); e: very rare (< 0.01%); f: unknown). Reference Active principle Commercial name ADR number 1. Abacavir Ziagen 3 2. Abacavir + lamivudine Kivexa 3 3. Abacavir + lamivudine + zidovudine Trizivir 3 4. Abatacept Orencia 3c 5. Acebotulol Prent 3b Sectral 3b 6. Aceclidin + timolol Glautimol 2,3 7. Aceclofenac Airtal 2e,3e Gladio 2e,3e Kafenac 2e,3e 8. Acemetacin Acemix 2,3,4 Solart 2,3,4 9. Acetazolamide Diamox 3,4 10. Acetylcysteine Acetilcisteina (*) 2c Altersol 2c Brunac 2c Dissolvin 2c Expectosol 2c Fluimucil 2c Frobemucil 2c KoKimucil mucol 2c Listemul 2c Hidonac 2c Mucofial 2c Mucomucil 2c Mucofrin 2c Solmucol 2c Tirocular 2c 11. Acetylsalicilic Acid Acido acetilsalicilico (*) 1,2 Aspirina 1,2 Aspirina dolore 1,2 Aspirina rapida 1,2 Aspirinetta 1,2 Aspro 500 1,2 Cardioaspirina 1,2 Cardioral 1,2 Cemirit 1,2 Neaprin febbre e dolore 1,2 Vivin 1,2 12. Acetylsalicilic acid + magnesium Ascriptin 1 13. Acitretine Neotigason 2 14. Acyclovir Aciclin 3 Aciclovir (*) 3 Acy 3 Acyvir 3 Alovir 3 Amodivyr 3 Avirase 3 Avix 3 Avyclor 3 Avyplus 3 Citivir 3 Cycloviran 3 Dravyr 3 Efriviral 3 Esavir 3 Euclivir 3 Fuviron 3 Herpesnil 3 Iliaclor 3 Immunovir 3 Neviran 3 Rexan 3 Riduvir 3 Sanavir 3 Voraclor 3 Zovirax 3 15. Adalimumab Humira 2c,3b 16. Adenosine Adenosina (*) 2d,2e Adenoscan 2d,2e Krenosin 2d,2e 17. Adrenaline Adrenalina (*) 3 FastjeKt 3 18. Adrenaline with articaine hydrochloride Alfacaina sp 1,2,3 Alfacaina 1,2,3 Cartidont 1,2,3 Citocartin 1,2,3 Sarticain 1,2,3 Septanest 1,2,3 Ubistesin 1,2,3 19. Agalsidase alfa - beta Febrazyme 2,3 20. Agomelatine Aldoxan 2c Thymanax 2c 21. Alemtuzumab Lemtrada 3a,3b 22. Alendronic acid Alendronato (*) 3a,3b Adronat 3a,3b Dronal 3a,3b Genalen 3a,3b 23. Alfentanil Fentalim 3 24. Alfuzosin hydrochloride Mittoval 3 Xatral 3 25. AlisKiren Rasilez 3 TeKturna 3 26. Alitritinoin Toctino 2a,2b 27. Alizapride hydrochloride Limican 3 28. Allopurinol Allopurinolo (*) 3 Allurit 3 Zyloric 3 29. Almotriptan Almogran 2c,3b Almotrex 2c,3b 30. Alpha 1 - antitrypsin Prolastina 3 31. Alphacalcidol Alpha D3 3 Dediol 3 Deril 3 Diseon 3 Diserinal 3 Geniad 3 Ostidil D3 3 Sefal 3 32. Alprazolam Alpravecs 3b Alprazig 3b Alprazolam(*) 3b Frontal 3b Mialin 3b Valeans 3b Xanax 3b 33. Amantadine hydrochloride Mantadan 3 34. Ambroxol hydrochloride Ambroxol big 3 Ambroxolo (*) 3 Atus 3 Broxol 3 Secretil 3 Surfactal 3 35. Amifostine Ethyol 3 36. AmiKacin Amicasil 1 AmiKacina teva 1 AmiKan 1 BbK8 1 Chemacin 1 LiKacin 1 Lukadin 1 MediamiK 1 Migracin 1 MiKan 1 MiKavir 1 NeKacin 1 37. AmiKacin sulphate Dramigel 1 LiKacin gel 1 38. Amiloride + hydrochlorothiazide Moduretic 2,3 39. Amiloride hydrochloride + furosemide Co-amilofruse 1,2 40. Aminophylline (intravenous use) Aminofillina (*) 3 Aminomal 3 Tefamin 3 41. Amiodarone hydrochloride Amiodar 1,3 Amiodarone (*) 1,3 Cordarone 1,3 42. Amisulpride Deniban 3 Solian 3 Sulamid 3 43. Amitriptyline + chlordiazepoxide Limbitryl 2,3 Sedans 2,3 44. Amitriptyline hydrochloride Adepril 2,3 Laroxyl 2,3 Triptizol 2,3 45. Amitriptyline hydrochloride + perphenazine Mutabon ansiolitico 2,3 Mutabon antidepressivo 2,3 Mutabon forte 2,3 Mutabon mite 2,3 46. Amlodipine Antacal 2,3 Monopina 2,3 Norvasc 2,3 47. Amoxycillin + clavulanate Abba 3 Amoxicillina + acido clavulanico (*) 3 Anival 3 Augmentin 3 Clavulin 3 Euticlavir 3 Homer 3 Klavox 3 Kruxade 3 Mondex 3 Moxivul 3 Neoduplamox 3 Xinamod 3 48. Amphotericin B Abelcet 1 Ambisome 1 Fungilin 1 Fungizone 1 49. Anagrelide Xagrid 2d,3b 50. Aniracetam Ampamet 3d 51. Aprepitant Emend 2,3 52. Aproclonidin Iopidine 3c 53. Argatroban monohydrate Novastan 1c 54. Aripiprazole Abilify 3b Clozapina (*) 3b Leponex 3b 55. Atazanavir Reyataz 3c 56. Atenolol Atenol 3 Atenololo (*) 3 Atermin 3 Seles beta 3 Tenomax 3 Tenormin 3 57. Atenolol + diuretics Atenigron 3 Atenololo/Clortalidone (*) 3 Atinorm 3 Carnian 3 Clortanol 3 Diube 3 Eupres 3 Eupres mite 3 Igroseles 3 Nor-Pa 3 Normopress 3 Target 3 Tenoretic 3 58. Atomoxetine Strattera 3 59. Atorvastatin Torvast 2,3 Totalip 2,3 60. Atosiban Tractocile 3b 61. Atropine sulphate Atropina solfato 3 Atropina lux 3 Atropina 1% 3 Farmigea 3 62. Axitinib Inlyta 2a 63. Azathioprine Azatioprina (*) 3 64. Azithromycin Azeptin 1,(3d) Aziprome 1,(3d) Azitredil 1,(3d) Azitroerre 1,(3d) Azitromicina(*) 1,(3d) Azitrox 1,(3d) Azylung 1,(3d) Azyter 1,(3d) Batif 1,(3d) Cinetrin 1,(3d) Macrozit 1,(3d) Portex 1,(3d) Rezan 1,(3d) Ribotrex 1,(3d) Tetris 1,(3d) Trozamil 1,(3d) Trozocina 1,(3d) Zimacrol 1,(3d) Zindel 1,(3d) Zitrobiotic 1,(3d) Zitrogram 1,(3d) Zitromax 1,(3d) 65. Aztreonam Azactam 2e,3 Cayston 2e,3 Primbactam 2e,3 66. Bacitracin + neomycin Bimixin 1 Orobicin 1 67. Baclofen Lioresal 3 68. Belatacept Nulojix 3a,3b 69. Benazepril + hydrochlorothiazide Cibadrex 2c,3b Tensadiur 2c,3b Zinadiur 2c,3b 70. Benazepril hydrochloride Cibacen 2,3 Tensanil 2,3 Zinadril 2,3 71. Betamethasone Beben 3 Bentelan 3 Beta 21 3 Betamesol 3 Betametasone dipropionato (*) 3 Betametasone farmacologico milanese 3 Betesil 3 Bettamousse 3 Celestone 3 Cortiflam 3 Diprosone 3 Ecoval 3 72. Betamethasone + bekanamicin + tetryzolin Visumetazone antibiotico 1 73. Betamethasone + clorfenamin Visumetazone antistaminico 2,3 74. Betamethasone + tetryzolin Visumetazone decongestionante 3 75. Bexarotene Targretin 3c 76. Bezafibrate Bezalip 3 77. Bilastine Ayrinal 2c,3c Olisir 2c,3c Robilas 2c,3c 78. Biperiden hydrochloride Akineton 3 79. Bisoprolol fumarate Bisoprololo Eg 3b Cardicor 3b Concor 3b Congescor 3b Pluscor 3b Sequacor 3b 80. Bisoprolol fumarate + diuretics Lodoz 3c 81. Boceprevir Victrelis 2a,2b 82. Bortezomib Velcade 3a,3b 83. Bosutinib Bosulif 2c 84. Botulinum toxin A Azzalure 2c,3b Bocouture 2c,3b Botox 2c,3b Dysport 2c,3b Neurobloc 2c,3b Vistabex 2c,3b Xeomin 2c,3b 85. Brimonidine tartrate Alphagan 3b 86. Brimonidine tartrate + timolole Combigan 3c 87. Brinzolamide Azarga 2c,3c Azopt 2c,3c 88. Brinzolamide + brimonidine Simbrinza 3c 89. Brivaracetam Nubriveo 3a,3b 90. Bromazepam Bromazepam (*) 3 Compendium 3 Lexotam 3 91. Bromocryptina mesylate Bromocriptina dorom 2d,3 Parlodel 2d,3 92. Bromperidol Impromen 3 93. Brotizolam Lendormin 3 Nimbisan 3 94. Buflomedil hydrochloride Buflan 3e Buflocit 3e Buflocit retard 3e Flomed 3e Irrodan 3e Irrodan ritardo 3e Loftil 3e Loftil plus 3e 95. Bupivacaine + adrenaline Bupicain + adrenalina 3 Bupiforan + adrenalina 3 Bupisen + adrenalina 3 Bupisolver + adrenalina 3 Bupixamol + adrenalina 3 96. Bupivacaine hydrochloride Bupibil 1,2,3 Bupicain 1,2,3 Bupiforan 1,2,3 Bupiforan heavy 1,2,3 Bupisen 1,2,3 Bupisolver 1,2,3 Bupivacaina (*) 1,2,3 Bupixamol 1,2,3 Fisiopharma 1,2,3 Marcaina 1,2,3 Marcaina iperbarica 1,2,3 97. Buprenorphine Subutex 2d,3b Temgesic 2d,3b Transtec 2d,3b 98. Bupropion Zyban 2c,3b 99. Buserelin Suprefact 3,4 Suprefact depot 3,4 Suprefact depot 3 mesi 3,4 Suprefact nasale 3,4 100. Buspirone hyrochloride Buspar 2a,2b,3b 101. Butizide + canrenoate potassium Kadiur 3c 102. Buxamina Gamibetal 3 103. Buxamina + diazepam Gamibetal plus 3 104. Buxamina + fenobarbital + fenitoina Gamibetal complex 3 105. Cabazitaxel Jevtana 2,3 106. Cabergoline Actualene 3b Cabaser 3b Cabergolina (*) 3b Dostinex 3b 107. Cabozantinib Cabometyx 2a,2b Cometriq 2a,2b 108. Cadralazina Cadraten 3 109. Calcitriol Calcijex 3 Calcitriolo (*) 3 Difix 3 Rocaltrol 3 TriKal 3 110. Calcium acetate + magnesium carbonate Osvaren 3c 111. Calcium carbonate + cholecalciferol (Vitamin Biocalcium D3 3 D3) Cacit vitamina D3 3 Cadtre 3 Calcicol D3 3 Calcidon 3 Calciocarbonato + Vitamina D3 (*) 3 Calcium D3 Sandoz 3 Calma D3 3 Carbo D3 3 Ditrost 3 Eurocal D3 3 Ideos 3 Kalaz D3 3 Metocal Vit D3 3 Natecal D3 3 Orotre 3 Tonacal D3 3 Urtotre 3 112. CanaKinumab Ilaris 3a,3b 113. Candesartan + diuretics Blopresid 3 Ratacand plus 3 114. Candesartan cilexetil Blopress 3 Ratacand 3 115. Cannabis extract Sativex 3a,3b 116. Capecitabine Capecitabina (*) 3c Xeloda 3c 117. Capreomycin Capastas 2 118. Captopril Acepress 3 Capoten 3 Captopril (*) 3 119. Captopril + diuretics Acediur 3c Aceplus 3c Aceplus mite 3c Captopril id (*) 3c Captopril idroclorotiazide ratiopharm 3c 120. Carbamazepine Carbamazepina (*) 3e Tegretol 3e 121. Carboplatin Carboplatino (*) 1 Paraplatin 1 122. Carboprost Hemabate 2c,3c 123. Carlfizomib Kyprolis 2a,2b 124. Carvedilol Caravel 3e Carvedilolo (*) 3e Carvipress 3e Colver 3e Curcix 3e Dilatrend 3e Dilocar 3e Omeria 3e 125. Catumaxomab Removab 3a,3b 126. Cefaclor Altaclor 3d Bacticef 3d Bactigram 3d Cefaclor (*) 3d Cefacloro sandoz 3d Cefulton 3d Clorad 3d Clorazer 3d Geniclor 3d Kliacef 3d Lafarclor 3d Macovan 3d Necloral 3d Omaspir 3d Oralcef 3d Panacef 3d Panacef Rm 3d Performer 3d Selviclor 3d TaKecef 3d Tibifor 3d Valeclor 3d 127. Cefadroxil Cefadril 3 Oradroxil 3 128. Cefazolin sodium Cefamezin 3 Cefazil 3 Cefazolina (*) 3 Cromezin 3 129. Cefepime Cepim 2d,3d Cepimex 2d,3d Maxipime 2d,3d 130. Cefixime Cefixoral 3 Suprax 3 Unixime 3 131. Cefonicid disodium Cefodie 3 Cefonicid (*) 3 Cefoplus 3 Chefir 3 Davcef 3 Emidoxin 3 Fonicid 3 Krucef 3 Lisa 3 Maxid 3 Modiem 3 Monobiotic 3 Necid 3 NoKid 3 Praticef 3 RaiKocef 3 Sintocef 3 Sofarcid 3 Valecid 3 132. Cefoperazone sodium Bioperazione 3d Dardum 3d 133. Cefotaxime Aximad 3 Batixim 3 Cefomit 3 Cefotaxima (*) 3 Cefotaxime (*) 3 Claforan 3 Lirgosin 3 Refotax 3 Salocef 3 Spectrocef 3 Taxime 3 Zariviz 3 Zimanel 3 134.
Load more

Recommended publications
  • Dental Management of Patients with Inherited Bleeding Disorders: a Multidisciplinary Approach
    Dental management of patients with inherited bleeding disorders: a multidisciplinary approach Hassan Abed, BDS, MSc ¢ Abdalrahman Ainousa, BDS, MSc Bleeding disorders can be inherited or acquired and leeding disorders can result from inherited genetic demonstrate different levels of severity. Dentists may be defects or be acquired due to use of anticoagulant med- called on to treat patients who have bleeding disor- ications or medical conditions such as liver dysfunc- ders such as hemophilia A and von Willebrand disease B 1-3 tion, chronic kidney disease, and autoimmune disease. During (vWD). Dental extraction in any patient with clotting blood vessel injury, hemostasis relies on interactions between factor defects can result in a delayed bleeding episode. the vascular vessel wall and activated platelets as well as clot- 4 Local hemostatic measures provide effective results in ting factors. Any marked defect at one of these stages results a majority of cases but are insufficient in patients with in bleeding disorders. Vascular wall defects, platelet defects, severe hemophilia A and vWD. Therefore, consultation or deficiency of clotting factors can affect the severity level of 5 with the patient’s hematologist is required to ensure bleeding episodes. Thus, patients may have mild, moderate, or preoperative prophylactic coverage. Dental care provid- severe episodes of bleeding. ers have to be aware of any signs of bleeding disorders and refer patients for further medical investigations. This Sources of inherited bleeding disorders article aims to provide dental care providers with the Vascular wall defects knowledge to manage patients with inherited bleeding A patient’s bleeding disorder may be unrecognized, and bleeding disorders, especially hemophilia A and vWD.
    [Show full text]
  • Update on Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
    J Bras Pneumol. 2015;41(5):454-466 http://dx.doi.org/10.1590/S1806-37132015000000152 REVIEW ARTICLE Update on diagnosis and treatment of idiopathic pulmonary fibrosis José Baddini-Martinez1, Bruno Guedes Baldi2, Cláudia Henrique da Costa3, Sérgio Jezler4, Mariana Silva Lima5, Rogério Rufino3,6 1. Divisão de Pneumologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brasil. 2. Divisão de Pneumologia, Instituto do Coração, Hospital das Clínicas, ABSTRACT Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil. Idiopathic pulmonary fibrosis is a type of chronic fibrosing interstitial pneumonia, of 3. Disciplina de Pneumologia e Tisiologia, unknown etiology, which is associated with a progressive decrease in pulmonary Faculdade de Ciências Médicas, function and with high mortality rates. Interest in and knowledge of this disorder have Universidade do Estado do Rio de grown substantially in recent years. In this review article, we broadly discuss distinct Janeiro, Rio de Janeiro, Brasil. aspects related to the diagnosis and treatment of idiopathic pulmonary fibrosis. We 4. Ambulatório de Pneumologia, Hospital list the current diagnostic criteria and describe the therapeutic approaches currently Ana Nery, Salvador, Brasil. available, symptomatic treatments, the action of new drugs that are effective in slowing 5. Ambulatório de Doenças Pulmonares Intersticiais, Hospital do Servidor the decline in pulmonary function, and indications for lung transplantation. Público Estadual de São Paulo, São Keywords: Idiopathic pulmonary fibrosis/diagnosis; Idiopathic pulmonary fibrosis/therapy; Paulo, Brasil. Idiopathic pulmonary fibrosis/rehabilitation. 6. Programa de Pós-Graduação em Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Efficacy of 2% Lidocaine and 4% Articaine in Mandibular Molars with Different Pulp Diagnoses in the Mandibular Technique1
    Efficacy of 2% lidocaine and 4% articaine in mandibular molars with different pulp diagnoses in the mandibular technique1 Eficacia de la lidocaína al 2% y la articaína al 4% en molares mandibulares con diferentes diagnósticos pulpares en la técnica mandibular1 Adel Martínez Martínez2, Evelyn Freyle Granados3, Natalia Senior Carmona3 1 Paper submitted in partial fulfillment of the requirements for the degree of Endodontist 2 Assistant Professor, GITOUC Group, School of Dentistry, Universidad de Cartagena 3 DDS, Specialist in Endodontics, Postgraduate program in Endodontics, School of Dentistry, Universidad de Cartagena ABSTRACT Introduction: the inferior alveolar dental nerve block is the method most commonly used by endodontists to achieve local anesthesia during treatments. This study compared the efficacy of two anesthetic solutions: 2% lidocaine with 1:80,000 epinephrine and 4% articaine with 1:100,000 epinephrine in patients with different ARTICLES ORIGINAL pulp diagnoses requiring endodontic treatment. Method: an interventional, randomized clinical trial. The sample included 36 patients who were treated at the postgraduate endodontics service at the Universidad de Cartagena in the year 2016. Descriptive statistics and the Chi2 test were used for data analysis, using a limit of 0.05. Results: articaine showed a greater anesthetic effect in vestibular mucosa (88.9%) and tip of tongue (55.6%), compared with lidocaine. The rates of anesthetic success in the lidocaine and articaine groups were 5.6% and 22.2% respectively, but this difference was not statistically significant (p = 0.633). In teeth with normal pulp, the efficacy was 27.3%, and this value considerably decreased in teeth with asymptomatic and symptomatic irreversible pulpitis, with percentages of 5.8% and 12.5% respectively, although this difference was not statistically significant (p = 0.276).
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Comparative Evaluation of Lignocaine, Articaine and Ropivacaine for Proximal Paravertebral Anaesthesia in Cattle S.D
    International Journal of Science, Environment ISSN 2278-3687 (O) and Technology, Vol. 8, No 3, 2019, 674 – 679 2277-663X (P) COMPARATIVE EVALUATION OF LIGNOCAINE, ARTICAINE AND ROPIVACAINE FOR PROXIMAL PARAVERTEBRAL ANAESTHESIA IN CATTLE S.D. Chepte1, M.G. Thorat2*, S.P. Waghmare3, M.V. Ingawale4, S.P. Mehesare5 M.V. Joshi5 and F.A. Fani6 1PhD Scholar, 2Professor and Head, 3Hospital Superintendent, 4Assistant Professor and 5Rtd Professor and 6Hospital Registrar Department of Surgery and Radiology Post Graduate Institute of Veterinary and Animal Sciences, MAFSU Akola (M.S.) E-mail: [email protected] (*Corresponding Author) Abstract: Present study was conducted on 18 clinical case of cattle presented with various gastro-intestinal affections to TVCC, PGIVAS, Akola subjected for laparotomy surgical procedure. All clinical cases were randomly divided into three equal group (n=6) and proximal paravertebral nerve block was performed by using Lignocaine, Articaine and Ropivacaine. Comparative anaesthetic assessment of onset of action and duration of anaesthesia along with clinicophysiological parameters were evaluated. Keywords: Lignocaine, Articaine, Ropivacaine, Cattle, Paravertebral. INTRODUCTION Thoracolumbar paravertebral block is performed to anesthetize the surgical site for a flank laparotomy. This technique is preferable to infiltration anesthetic techniques because of the smaller volume of anesthetic agent required, production of a more extensive anesthesia of the abdominal wall and reduced postoperative swelling and hematoma (Rostami & Vesal 2011). In ruminants, flank region is the most common site for laparotomy; caesarian section, rumenotomy, intestinal obstruction, volvulus, ruminal fistula, foreign body syndrome and hernia etc. (Lee, 2006; Kumar, 2003). Paravertebral nerve block results effective analgesia in all layers of the abdominal wall while the tissue infiltration, inverted L block may not produce analgesia of all muscle layers as well as peritoneum specially in fat animals (Sloss and Dufty, 1977).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,844,355 B2 Somberg Et Al
    USOO684.4355B2 (12) United States Patent (10) Patent No.: US 6,844,355 B2 Somberg et al. (45) Date of Patent: Jan. 18, 2005 (54) OPTICALLY ACTIVE ISOMERS OF QUININE Catterall, (1992) Physiol. Rev. 72(supp):S15-S48. AND QUINDINE AND THEIR RESPECTIVE Chan et al., (1991) J. Chromatogr. 571:291-297. BIOLOGICALACTION Chen et al., (1998) Nature 392:293–296. (75) Inventors: John C. Somberg, Lake Forest, IL Coplen et al., (1991) Circulation 84:527. (US); Vasant Ranade, Libertyville, IL Drabowicz et al., (1984) “Chemical Abstracts” Phosphorus (US) Sulfur 16:2676–270 (XP002165239). Engler et al., (1985) Helv. Chim. Acta. 68:789–800. (73) Assignee: Academic Pharmaceuticals, Inc., Lake Ficker et al., (1998) Circ. Res. 82:386–395. Bluff, IL (US) Gellens et al., (1992) Proc. Natl. Acad. Sci. 89:554–558. (*) Notice: Subject to any disclaimer, the term of this Gutzwiller et al., (1973) “Chemical Abstracts” Helv. Chim. patent is extended or adjusted under 35 Acta. 79:1494–1503 (XP002165238). U.S.C. 154(b) by 0 days. Hartmann et al. (1994) Circ. Res. 75:114-122. Karle I.L. et al., (1981) Proc. Natl. Acad. Sci. 78:5938–5941. (21) Appl. No.: 10/168,919 Karle, J.M. (1997) Antimicrob. Agents Chemother. (22) PCT Filed: Dec. 22, 2000 41:791-794. Kiehn et al. (1996) Circulation 94:2572–2579. (86) PCT No.: PCT/US00/352.13 Krafte et al., (1994) Europ. J. Pharma. 266:245-254. S371 (c)(1), Li et al. (1996) Circ. Res. 78:689-696. (2), (4) Date: Oct. 30, 2002 Sanguinetti et al., (1990) J.
    [Show full text]
  • Local Anesthetic
    Sedation & Anesthesia in Dental Practice LOCAL ANESTHESIA: “30+ Years of Hits, Misses and Near MiSs- THE NATIONAL NETWORK for ORAL HEALTH ACCESS es” THE 2015 ANNUAL CONFERENCE Indianapolis, Indiana November 16th , 2015 Mel Hawkins, DDS, BScD AN Dentist / Dentist Anesthesiologist Toronto, ON Canada www.sedationdentistry.us [email protected] AGENDA 1 2 3 Anatomy, What can What’s new? Blocks, go wrong Paresthesia, Road and what reversing, Blocks, to do buffering, inhalational More about it? and more Blocks PART ANATOMY, BLOCKS, ROAD BLOCKS AND MORE BLOCKS THE ELUSIVE McDibular BLOCK …millions and millions served . Trivia: The dental local anesthesia industry combined now serves up 330 million cartridges every year in North America A=86% B=7% C=7% Inferior Alveolar Block “Conventional” as opposed to a “mandibular block” Relationship of: Conventional (inferior alveolar) Akinosi, closed mouth Gow-Gates “condylar neck” Hybrid, “mix and match” blocks Reasons for Failure Anatomical Variations: • Hard tissue anatomy • Connective tissue and Neurovascular anatomy Dr. George Gow-Gates, Dr. J. Watson, University of Sydney, Australia 3 Major Factors: •Internal Oblique Ridge •Sphenomandibular fascial barrier •Risks: Nerves, Arteries The distance between the internal and external oblique line of the mandible varies. Adapted from Dr. N. B. Jorgensen Netter, Grant’s Anatomy Anatomical Influences: The maxillary artery, passes through the high pterygomandibular triangle region The Question is: What is the risk of an intraarterial injection? Clinically Unlikely Internal Maxillary Artery Characteristics: • Thick smooth muscle wall • Well innervated • Constricts or arteriospasms, eliminates lumen • Artery is mobile within the anatomical area • Pulse pressure True Confessions Histology Horizontal X-S, level of Conventional I.A.N.Block Courtesy Dr.
    [Show full text]
  • Populationsweite Utilisationsuntersuchung in Den Chronischen Krankheitsbildern Hypertonie, Hyperlipid¨Amieund Typ 2 Diabetes Mellitus –
    Ruhr-Universit¨atBochum Prof. Dr. rer. nat. Hans J. Trampisch Dienstort: Abteilung f¨urMedizinische Informatik, Biometrie und Epidemiologie Populationsweite Utilisationsuntersuchung in den chronischen Krankheitsbildern Hypertonie, Hyperlipid¨amieund Typ 2 Diabetes Mellitus { Eine Studie des Projekts PUKO-BHD an der Medizinischen Universit¨atWien Inaugural-Dissertation zur Erlangung des Doktorgrades der Medizin einer Hohen Medizinischen Fakult¨at der Ruhr-Universit¨atBochum vorgelegt von: Lisanne M. Jandeck aus Herford 2014 Dekan: Prof. Dr. med. Albrecht Bufe Referent: Prof. Dr. rer. nat. Hans J. Trampisch Korreferent: Prof. Dr. med. J¨urgenWindeler Tag der M¨undlichen Pr¨ufung:09.02.2017 Abstract Jandeck Lisanne M. Populationsweite Utilisationsuntersuchung in den chronischen Krankheitsbildern Hypertonie, Hyperlipid¨amieund Typ 2 Diabetes Mellitus Problem: Hypertonie (HT), Hyperlipid¨amie(HL) und Typ 2 Diabetes Mellitus (DM) stellen die h¨aufigstenchronischen Erkrankungen in Osterreich¨ dar, besonders bei Uber-50j¨ahrigen.Die¨ Zielsetzung dieser Teilstudie Utilisation\ des Projekts mit " dem Titel PUKO-BHD { Pr¨avalenz, Utilisation, Kosten und Outcome bei Blut- " hochdruck, Hyperlipid¨amieund Typ 2 Diabetes Mellitus\ ist eine populationsweite epidemiologische Untersuchung zu der Utilisation von Arzneimitteln zur Behand- lung dieser Krankheiten, insbesondere in Bezug auf Mehrfachverschreibungen (dou- ble prescriptions, DP) und Verschreibungen von Kombinationen von Wirkstoffen, die (schwerwiegende) Wechselwirkungen erzeugen k¨onnen (drug-drug
    [Show full text]
  • Comparison of Articaine and Prilocaine Anestiesia by Infiltration in Maxillary and Mandibular Archles Daniel A
    Anesth Prog 37:230-237 1990 SCIENTIFIC REPORTS Comparison of Articaine and Prilocaine Anestiesia by Infiltration in Maxillary and Mandibular Archles Daniel A. Haas, DDS, PhD, David G. Harper, DDS, Michael A. Saso, DDS, and Earle R. Young, DDS, MSc Department of Anaesthesia, Faculty of Dentistry, University of Toronto Claims that labial infiltration of the local anesthetic It is commonly accepted that in order to achieve local articaine HCl (Ultracaine DS"M) results in anesthesia for procedures on teeth or buccal soft tissue anesthesia of mandibular pulpal as well as in the maxillary arch, administration of local anesthetics maxillary and mandibular lingual soft tissue have by buccal infiltration, also known as a paraperiosteal field never been scientifically substantiated. The aim of block, is routinely successful. Palatal soft tissue anesthesia this investigation was to evaluate these claims, by requires a separate palatal injection, a technique that is comparing articaine to a standard anesthetic, often painful for the patient. Any local anesthetic that prilocaine HCI (Citanest ForteTM). To investigate would permit use of buccal infiltration to gain palatal anes- this, a double blind, randomized study was thesia would be of great advantage in dentistry. For proce- conducted in healthy adult volunteers. In each dures in the mandibular arch, in adults, the thickness of volunteer, the ability to induce maxillary and buccal cortical bone precludes buccal infiltration ap- mandibular anesthesia following labial infiltration proaches producing pulpal or lingual soft tissue anesthe- with articaine was compared to prilocaine given sia, necessitating administration of local anesthetic by contralaterally. Anesthesia was determined by nerve block techniques.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]